Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Lupin Limited    LUPIN   INE326A01037

SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Lupin Limited : Lupin Looking for Acquisitions of up to $500 Million in US

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/01/2012 | 12:39pm CET

--Looking for buys in skin care, eye care, respiratory and women's health products

--Trying to expand pipeline of low-competition generic drugs for US market

(Adds executive's comments in 7th, 9th, 12th and 13th paragraphs, background and context elsewhere)

By Rumman Ahmed

BANGALORE--Lupin Ltd. (500257.BY) is looking to aggressively grow its business in the U.S. and is scouting for acquisitions of pharmaceutical brands and manufacturers, and seeking regulatory approval to sell a wider range of niche generic drugs.

The U.S. is Lupin's primary growth market, accounting for 35% of its sales.

The India drug maker is benefiting from a wave of patent expiries for popular drugs in the U.S. But to keep the business momentum going once the "patent cliff" wave wanes, Lupin is looking to acquire branded products that are much bigger that its previous purchases.

"We've looked at small-sized acquisition opportunities as well as opportunities in the $400 million-$500 million price range," group president Vineeta Gupta recently told Dow Jones Newswires.

Unlike most of its local rivals, Lupin's business model for the world's largest pharmaceuticals market is not limited to selling drug copies: It also sells branded products like antibiotic Suprax and anti-cholesterol drug Antara. While the branded products contribute about 25% of Lupin's U.S. revenue, they make up a larger share of its profit.

Lupin is looking for acquisitions to revive the momentum in the branded-products business at a time when existing brands are likely to come up against generic competition.

The company would prefer acquisitions in the areas of skin care, eye care, respiratory and women's health products, which are more in line with the company's commercial infrastructure in the U.S., Ms. Gupta said.

The company's 160-person sales force in the U.S. is focused on selling branded products to the pediatric and primary-care market segments.

Ms. Gupta, who also heads Lupin's U.S. unit, said Lupin had mulled acquiring eye-care company ISTA Pharmaceuticals Inc., but found it wasn't a "good fit."

Eye-products maker Bausch & Lomb Inc. purchased ISTA for about $500 million in cash in a deal that closed in June.

Lupin's previous acquisitions in the U.S. were much smaller in comparison. In 2009 it paid $38.61 million to bankrupt Oscient Pharmaceuticals Corp. for Antara, and acquired AllerNaze nasal spray from U.S.-based Collegium Pharmaceutical Inc. for an undisclosed amount.

As for its generic drugs business, Lupin is trying to move its pipeline to products that are exclusive and face less competition, Ms. Gupta said.

Lupin has already applied to sell generic versions of about 31 oral contraceptive products and some eye treatments. It has also filed the first generic drug application with the U.S. regulator for a skin care product in the January-March period, she added.

Benefits from selling these drugs, which have relatively high entry barriers and offer higher-than-average margins, are expected to kick in from the fiscal year starting next April.

Write to Rumman Ahmed at rumman.ahmed@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUPIN LIMITED
01/23 LUPIN : gets USFDA approval; stocks up 1.6%
01/14 LUPIN : Launches generic morphine sulfate in us
01/12 LUPIN : Gets fda nod for skin cream
01/03 LUPIN : Gets usfda nod for cevimeline capsules
01/02 LUPIN : receives FDA nod for generic Evoxac Capsules
2016 LUPIN : receives tentative approval for generic LivaloTablets
2016 ET500-2016 RANKINGS : Lupin limited
2016 LUPIN : Gets fda nod to sell ulcerative colitis tablets
2016 LUPIN : receives tentative approval for generic Giazo Tablets
2016 LUPIN : Gets tentative fda nod for drug in us
More news
Sector news : Pharmaceuticals - NEC
12:35a U.S. reaches settlement with Endo on pay-for-delay charges
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ( INR)
Sales 2017 173 389 M
EBIT 2017 37 299 M
Net income 2017 28 409 M
Debt 2017 48 843 M
Yield 2017 0,58%
P/E ratio 2017 23,29
P/E ratio 2018 20,14
EV / Sales 2017 4,14x
EV / Sales 2018 3,53x
Capitalization 669 666 M
More Financials
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 44
Average target price 1 725  INR
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Nilesh Deshbandhu Gupta Managing Director & Executive Director
Vinita Gupta Sharma Chief Executive Officer & Executive Director
Desh Bandhu Gupta Chairman
Ramesh Swaminathan Chief Financial Officer & Executive Director
Vijay Laxman Kelkar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LUPIN LIMITED0.00%9 827
JOHNSON & JOHNSON-1.13%309 896
ROCHE HOLDING LTD.0.39%200 025
PFIZER INC.-3.14%190 910
NOVARTIS AG-4.32%183 809
MERCK & CO., INC.4.99%170 419
More Results